Advertisement

Topics

MannKind Corporation Company Profile

10:20 EDT 26th March 2019 | BioPortfolio

MannKind Corporation (Nasdaq:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFREZZA(TM) and MKC253. MKC253 is currently in phase 1 clinical trials. In March 2009, MannKind submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of AFREZZA for the treatment of adults with Type 1 or Type 2 diabetes for the control of hyperglycemia. In March 2010, MannKind received a Complete Response to this NDA from the FDA requesting additional information. An End-of-Review meeting was held in June 2010 and MannKind is currently preparing its resubmission of the AFREZZA NDA. Other products in MannKind's pipeline include the cancer immunotherapy products MKC1106-PP and MKC1106-MT, which are currently in phase 1 clinical trials. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.


News Articles [180 Associated News Articles listed on BioPortfolio]

MannKind nets $37.6mm via FOPO

MannKind Corp. netted $37.6mm through the follow-on public offering of 26.7mm common shares at $1.50. The company also issued 26.7mm one-year warrants to buy one common share exercisable at $1.60. Man...

STAT Plus: Wait … what? Mannkind posts best-ever quarter of inhaled insulin product sales

For the first time, Mannkind managed not to lose money on each Afrezza cartridge sold.

New patent for Mannkind drug AFREZZA

Annual Drug Patent Expirations for AFREZZA Afrezza is a drug marketed by Mannkind and is included in one NDA. It is available from one supplier. There are thirty-seven patents protecting… The post N...

5 Top Weekly NASDAQ Biotech Stocks: MannKind Soars 83 Percent

MannKind, Evofem Biosciences, Arbutus Biopharma, Infinity Pharmaceuticals and VBI Vaccines were last week's top gainers on the NASDAQ Biotechnology Index. The post 5 Top Weekly NASDAQ Biotech Stocks:...

5 Top Weekly NASDAQ Biotech Stocks: MannKind Leads the Pack

MannKind, Sierra Oncology, Eiger BioPharmaceuticals, Aevi Genomic Medicine and KalVista Pharmaceuticals were last week's top gainers on the NASDAQ Biotechnology Index. The post 5 Top Weekly NASDAQ Bi...

‘Revamped’ MannKind secures $105m licensing deal, plans Afrezza expansion

MannKind Corporation, of Afrezza fame, and United Therapeutics have signed an exclusive licensing and collaboration agreement for dry powder pulmonary hypertension products.

MannKind Corporation expanding into the cannabinoid space

MannKind Corporation (NASDAQ:MNKD) CEO Michael Castagna sat down with Proactive Investors at the 11th Annual BioTech Showcase in San Francisco. The California-based biopharma develops inhaled ther...

United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement

United Therapeutics (Nasdaq: UTHR) and MannKind (Nasdaq: MNKD) announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization ...

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [184 Associated Companies listed on BioPortfolio]

MannKind Corporation

MannKind Corporation (Nasdaq:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its ...

Toshiba Corporation

Toshiba Medical Systems Corporation is a leading worldwide provider of medical diagnostic imaging systems and comprehensive medical solutions, such as CT, X-ray and vascular, ultr...

MannKind

MannKind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product c...

Bruker Daltonics

Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analy...

MannKind Corporation and Tolero Pharmaceuticals

Tolero is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat and cure cancer and other life-threatening diseases. Tolero has use...

More Information about "MannKind Corporation" on BioPortfolio

We have published hundreds of MannKind Corporation news stories on BioPortfolio along with dozens of MannKind Corporation Clinical Trials and PubMed Articles about MannKind Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MannKind Corporation Companies in our database. You can also find out about relevant MannKind Corporation Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Corporate Database Quicklinks



Searches Linking to this Company Record